Understanding how SGLT2 inhibitors change the kidney’s filtering process
For decades, medications designed to treat type 2 diabetes focused entirely on insulin—either helping the pancreas make more of it, or helping the body’s cells respond better to it. Empagliflozin, part of a newer class of drugs known as SGLT2 inhibitors, takes a completely different approach. Instead of working through the pancreas or the liver, empagliflozin uses the kidneys as its primary mechanism to lower blood sugar.
Every day, your kidneys filter nearly 180 liters of fluid from your blood. During this massive filtration process, vital substances like glucose (sugar), sodium, and amino acids are pushed out of the blood and into the tiny tubules of the kidney. However, the body is highly efficient and does not want to waste this valuable energy. Therefore, specific transporter proteins line these tubules and reabsorb almost 100 percent of the filtered glucose back into the bloodstream. The most active of these transporters is called Sodium-Glucose Co-Transporter-2 (SGLT2).
In a person with type 2 diabetes, the kidneys are often reabsorbing large amounts of glucose, keeping blood sugar levels chronically high. Empagliflozin works by intentionally blocking this SGLT2 transporter protein. When the transporter is disabled, the kidney loses its ability to pull glucose back into the blood. Instead, the glucose remains in the tubule fluid and is simply flushed out of the body when you urinate. It is a highly mechanical, efficient way of lowering blood sugar completely independently of insulin.
Shifting excess glucose from the blood into the urine
By blocking the reabsorption process, empagliflozin causes the body to excrete approximately 70 to 90 grams of glucose in the urine every single day. This steady removal of sugar has immediate and profound effects on the patient’s metabolic state. The most obvious result is a reliable drop in blood sugar levels, which helps bring the HbA1c measurement down into a safer target range.
However, the benefits extend beyond just glucose control. Glucose contains calories. By flushing 70 to 90 grams of glucose down the toilet every day, the body is simultaneously flushing away roughly 300 to 400 calories. Because of this continuous calorie loss, most patients taking empagliflozin experience modest but sustained weight loss. This is a significant advantage, as excess weight is a major driver of insulin resistance in type 2 diabetes.
Furthermore, because the SGLT2 transporter moves both sodium and glucose together, blocking it also causes the kidneys to excrete slightly more sodium and water. This mild diuretic effect reduces the overall fluid volume in the cardiovascular system, which in turn leads to a modest, beneficial drop in blood pressure. Thus, through a single mechanism in the kidney, empagliflozin lowers blood sugar, promotes weight loss, and reduces blood pressure.
The unexpected discovery of profound kidney protection
When SGLT2 inhibitors like empagliflozin were first approved, they were celebrated for their unique method of lowering blood sugar. However, the true breakthrough occurred several years later when long-term clinical trials revealed something unexpected: these drugs provided massive, unprecedented protection against the progression of chronic kidney disease (CKD).
Diabetic nephropathy (kidney disease caused by diabetes) is a devastating complication. High blood sugar damages the delicate filtering units (glomeruli) in the kidneys. Specifically, it causes the pressure inside these tiny filters to rise to dangerous levels, eventually causing them to fail and leak protein into the urine. For a long time, doctors had very few tools to slow this decline.
Empagliflozin changed this narrative. By changing how sodium is handled in the kidney tubule, the medication triggers a feedback loop that causes the blood vessel entering the glomerulus to constrict slightly. This subtle constriction dramatically reduces the hyper-pressure inside the delicate filter. By relieving this physical stress, empagliflozin dramatically slows the decline of kidney function, reduces protein leakage, and significantly delays the need for dialysis. The evidence for this protection is so robust that nephrologists (kidney specialists) now routinely prescribe empagliflozin to protect the kidneys, even in patients who do not have diabetes.
Managing the risk of urinary tract and genital infections
While the mechanism of excreting glucose through the urine is highly effective, it does create a specific set of side effects that patients must manage. Because the urine of a patient taking empagliflozin is constantly laden with high amounts of sugar, it creates an ideal, nutrient-rich environment for bacteria and yeast to thrive.
The most common side effects associated with empagliflozin are genital mycotic infections (yeast infections) in both women and men (particularly uncircumcised men). These infections can be uncomfortable and bothersome but are generally easily treated with standard over-the-counter or prescription antifungal creams or oral medications. Some patients may experience these infections recurrently, which occasionally requires stopping the medication.
There is also a slightly increased risk of urinary tract infections (UTIs). While most of these are standard, easily treated lower tract infections, there is a very rare risk of severe infections spreading to the kidneys (pyelonephritis). Patients are instructed to practice excellent personal hygiene and to contact their doctor promptly if they experience symptoms such as burning during urination, frequent urging to urinate, or pelvic pain.
The importance of hydration and blood pressure monitoring
As mentioned earlier, empagliflozin acts as a mild diuretic by causing the kidneys to excrete more sodium and water alongside the glucose. While this is beneficial for lowering blood pressure, it means patients must be mindful of their hydration status to avoid complications.
If a patient does not drink enough fluids, the continuous diuretic effect can lead to volume depletion or mild dehydration. This can cause symptoms such as dizziness, lightheadedness (especially when standing up quickly), and fatigue. In older adults, or those taking other diuretic medications (water pills) for blood pressure, this risk of dehydration is amplified and can occasionally cause a temporary drop in kidney function.
Patients starting empagliflozin are generally advised to maintain adequate daily hydration—drinking water consistently throughout the day. Your doctor may also adjust the doses of your other blood pressure medications to prevent your pressure from dropping too low. Being aware of how you feel when standing up and ensuring your urine remains pale yellow are practical ways to monitor your hydration while on this therapy.
Recognizing the rare but serious risk of euglycemic DKA
One of the most serious, albeit rare, risks associated with the entire class of SGLT2 inhibitors is a condition known as euglycemic diabetic ketoacidosis (DKA). DKA is a life-threatening emergency where the body, unable to use glucose for fuel, begins rapidly breaking down fat. This process produces toxic acids called ketones, which build up in the blood.
Traditionally, DKA occurs when blood sugar levels are extremely high (usually in type 1 diabetes). However, empagliflozin can trigger DKA even when a patient’s blood sugar readings appear completely normal or only slightly elevated—hence the term ‘euglycemic’ (normal glucose) DKA. Because the blood sugar numbers do not look alarming, the condition can easily be missed or misdiagnosed by both the patient and emergency room staff.
The risk of DKA on empagliflozin increases significantly during times of physical stress, such as severe illness, infection, extreme fasting (like preparing for a colonoscopy), or surgery. Patients are explicitly instructed to temporarily stop taking empagliflozin several days before any scheduled surgery or during periods of acute illness where they cannot eat or drink normally. Symptoms of DKA include severe nausea, vomiting, abdominal pain, extreme fatigue, and difficulty breathing. If these occur, patients must seek immediate emergency medical care and explicitly inform the staff they are taking an SGLT2 inhibitor.
How empagliflozin fits into a broader diabetes care plan
In the modern treatment algorithms for type 2 diabetes, empagliflozin is rarely used in isolation. It is most commonly prescribed as a powerful add-on therapy, typically layered on top of foundational medications like metformin.
Because empagliflozin works completely independently of insulin, it can be safely and effectively combined with almost any other diabetes medication, including GLP-1 agonists (like semaglutide) and insulin itself. When combined with insulin, empagliflozin can often help reduce the total daily dose of insulin required, which mitigates the weight gain typically associated with intensive insulin therapy.
Furthermore, much like the GLP-1 class, empagliflozin has demonstrated massive cardiovascular benefits. Large trials showed that it significantly reduces the risk of cardiovascular death and hospitalization for heart failure. Consequently, international guidelines now strongly recommend starting an SGLT2 inhibitor like empagliflozin in patients with type 2 diabetes who also have established cardiovascular disease, heart failure, or chronic kidney disease, regardless of their current HbA1c levels.
Talking to your doctor about comprehensive metabolic health
Empagliflozin exemplifies the shift in how modern medicine views type 2 diabetes. The goal is no longer just controlling glucose; it is comprehensive metabolic and organ protection. We now have medications that simultaneously lower blood sugar, support weight loss, preserve kidney function, and prevent heart failure admissions.
If you have type 2 diabetes and are concerned about your kidney health or your heart, empagliflozin is a therapy worth discussing with your prescriber. The conversation should include an honest assessment of your ability to manage the hygiene requirements to prevent yeast infections, your current hydration habits, and your understanding of the sick-day rules required to prevent DKA.
When used correctly and monitored appropriately, empagliflozin is an incredibly potent tool that fundamentally changes the trajectory of diabetic complications. By protecting the delicate filters in the kidneys and easing the workload on the heart, it offers a level of comprehensive protection that was unimaginable just a decade ago.
This article is for informational purposes only and is not a substitute for medical advice from a licensed healthcare professional. Always consult your doctor or pharmacist before starting, changing, or stopping any medication.